Recently, Nami Vision, a directly invested enterprise of Nanjing Venture Capital Group, announced exciting news: its independently developed CompoundEye 24, the world's first phased array CT product, officially obtained the Class III Medical Device Registration Certificate issued by the National Medical Products Administration (NMPA) on December 31, 2025. This milestone breakthrough not only marks the commercialization of a new technology system in the global medical imaging field, but also opens up a brand-new path for clinical precise diagnosis.

As the world's inaugural phased array CT product, the core competitiveness of CompoundEye 24 lies in its "full independent controllability"—from the top-level design of the core technical architecture, to the R&D and mass production of key components, and to the overall intelligent manufacturing of the product, all are 100% independently completed by Nami Vision. The product has completely broken free from reliance on external technologies and supply chains, and successfully built a high-barrier technological moat. The smooth approval of the product means that it meets national relevant requirements in core dimensions such as safety, clinical effectiveness and quality management system, clearing the way for its promotion in the domestic market, and is expected to provide a more efficient and precise new solution for imaging diagnosis for the global medical industry.

In August 2025, Nanjing Venture Capital Group participated in the hundreds-of-millions-yuan investment in Nami Vision by the urban-rural joint SPV through the Nanjing Major Project Fund under its management. Yan Peng'an, General Manager of the Third Investment Department of the Group, said: "Warm congratulations to Nami Vision on the successful approval of the world's first phased array CT! This product has achieved a disruptive breakthrough in the high-end medical imaging market. Relying on high-efficiency imaging technology, flexible clinical adaptability and the advantage of a fully independent and controllable supply chain, it is expected to break the long-term monopoly of foreign brands and reshape the industry competition rules with China's independent innovation strength. Through investing in Nami Vision, Nanjing Venture Capital Group will effectively drive the coordinated upgrading of the local upstream and downstream industrial chains in Nanjing, gather talents and industrial resources, and enhance Nanjing's competitiveness in the field of high-end medical equipment."